retatrutide mechanism triple agonist gip glp-1 glucagon retatrutide What Is Retatrutide? The Peptide Explained Retatrutide: How the Triple Agonist
Description
Semaglutide 2.4mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 1517% mean weight loss (WL) with evidence of cardioprotection
It helps maintain gut health, support metabolic performance, and promote immune and internal balance over time.
However, individuals with obesity or insulin resistance may experience enhanced clinical and cognitive outcomes
Ozempic alternatives for weight loss span branded medications, compounded formulations, and lifestyle-based approaches
